Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2025 Jun;40(3):307-341.
doi: 10.3803/EnM.2025.2461. Epub 2025 Jun 24.

2025 Korean Thyroid Association Clinical Management Guideline on Active Surveillance for Low-Risk Papillary Thyroid Carcinoma

Affiliations
Practice Guideline

2025 Korean Thyroid Association Clinical Management Guideline on Active Surveillance for Low-Risk Papillary Thyroid Carcinoma

Eun Kyung Lee et al. Endocrinol Metab (Seoul). 2025 Jun.

Abstract

The increasing detection of papillary thyroid microcarcinoma (PTMC) has raised concerns regarding overtreatment. For low-risk PTMC, either immediate surgery or active surveillance (AS) can be considered. To facilitate the implementation of AS, the Korean Thyroid Association convened a multidisciplinary panel and developed the first Korean guideline. AS is recommended for adults with pathologically confirmed Bethesda V-VI PTMC who have no clinical evidence of lymph node or distant metastasis, gross extrathyroidal extension, invasion of the trachea or recurrent laryngeal nerve, or aggressive histology. A baseline assessment requires high-resolution neck ultrasound performed by experienced operators to exclude extrathyroidal extension, tracheal or recurrent laryngeal nerve invasion, and lymph node metastasis; contrast-enhanced neck computed tomography is optional. Patient characteristics, including age, comorbidities, and the capacity for long-term follow-up, should be thoroughly assessed. Shared decision-making should carefully weigh the benefits and risks of surgery versus AS, considering expected oncologic outcomes, potential complications, quality of life, anxiety, medical costs, and patient preference. Follow-up involves neck ultrasound and thyroid function tests every 6 months for 2 years and annually thereafter. Disease progression, defined as significant tumor growth or newly detected nodal or distant metastasis, warrants surgery. Despite remaining uncertainties, this guideline provides a structured framework to ensure oncologic safety and supports patient-centered AS.

Keywords: Active surveillance; Guideline; Korean; Papillary thyroid microcarcinoma; Thyroid neoplasms.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

Young Joo Park is an editor-in-chief of the journal. But she was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

Figures

Fig. 1.
Fig. 1.
Ultrasound-based appropriateness criteria for active surveillance in papillary thyroid microcarcinoma. Subcapsular tumors are defined as lesions that abut either the anterior or posterior thyroid capsule. A tumor in contact with the anterior capsule (yellow line) is categorized as an anterior subcapsular tumor, whereas tumors that touch the posteromedial capsule (red line) or the posterolateral capsule (blue line) are classified as posteromedial and posterolateral subcapsular tumors, respectively. Modified from Lee et al. [32]. TEG, tracheoesophageal groove.
Fig. 2.
Fig. 2.
Algorithm for follow-up during active surveillance (AS). US, ultrasound; ETE, extrathyroidal extension; LN, lymph node.

Similar articles

References

    1. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA. 2017;317:1338–48. - PMC - PubMed
    1. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. Lyon: International Agency for Research on Cancer; 2024. Global Cancer Observatory: Cancer Today [Internet] [cited 2025 Jun 10]. Available from: https://gco.iarc.who.int/today.
    1. Park EH, Jung KW, Park NJ, Kang MJ, Yun EH, Kim HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2022. Cancer Res Treat. 2025;57:312–30. - PMC - PubMed
    1. Choi YM, Lee J, Kwak MK, Jeon MJ, Kim TY, Hong EG, et al. Recent changes in the incidence of thyroid cancer in Korea between 2005 and 2018: analysis of Korean National Data. Endocrinol Metab (Seoul) 2022;37:791–9. - PMC - PubMed
    1. Megwalu UC, Moon PK. Thyroid cancer incidence and mortality trends in the United States: 2000-2018. Thyroid. 2022;32:560–70. - PubMed

Publication types

MeSH terms

Supplementary concepts